Multispecific Biologics Design
Multiple targets
Pre-clinicalActive
Key Facts
About Nabla Bio
Nabla Bio is a private, pre-clinical stage biotech leveraging an integrated AI and wet-lab platform to design novel antibodies and multispecific biologics. Its core technology, the JAM generative modeling system, is trained on massive protein data and refined with proprietary human-relevant assays to enable epitope-precise, de novo drug design. The company operates a platform-plus-partnership business model, collaborating with pharmaceutical partners while advancing its own pipeline, and is positioned to tackle historically difficult drug targets like GPCRs and ion channels.
View full company profileOther Multiple targets Drugs
| Drug | Company | Phase |
|---|---|---|
| Novel Antibody Discovery Platform | Nabla Bio | Pre-clinical |
| Hard-to-Drug Target Programs (e.g., GPCRs) | Nabla Bio | Pre-clinical |